This company listing is no longer active
LXG.H Stock Overview
LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
LexaGene Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.10 |
| 52 Week High | CA$0.30 |
| 52 Week Low | CA$0.065 |
| Beta | 2.25 |
| 1 Month Change | 0% |
| 3 Month Change | -19.23% |
| 1 Year Change | -43.24% |
| 3 Year Change | -87.20% |
| 5 Year Change | -91.60% |
| Change since IPO | -58.00% |
Recent News & Updates
Recent updates
It's Unlikely That LexaGene Holdings Inc.'s (CVE:LXG) CEO Will See A Huge Pay Rise This Year
Feb 02
We're A Little Worried About LexaGene Holdings' (CVE:LXG) Cash Burn Rate
Oct 07Here's Why We're Not Too Worried About LexaGene Holdings' (CVE:LXG) Cash Burn Situation
May 17We Think LexaGene Holdings (CVE:LXG) Can Afford To Drive Business Growth
Feb 01Shareholder Returns
| LXG.H | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | 0% | -2.0% | 1.7% |
| 1Y | -43.2% | -14.7% | 16.1% |
Return vs Industry: LXG.H underperformed the Canadian Medical Equipment industry which returned -1% over the past year.
Return vs Market: LXG.H underperformed the Canadian Market which returned -2.4% over the past year.
Price Volatility
| LXG.H volatility | |
|---|---|
| LXG.H Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 13.8% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: LXG.H's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine LXG.H's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 33 | Jack Regan | www.lexagene.com |
LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets; and assay panels. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection.
LexaGene Holdings Inc. Fundamentals Summary
| LXG.H fundamental statistics | |
|---|---|
| Market cap | CA$14.78m |
| Earnings (TTM) | -CA$11.53m |
| Revenue (TTM) | CA$140.83k |
104.9x
P/S Ratio-1.3x
P/E RatioIs LXG.H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXG.H income statement (TTM) | |
|---|---|
| Revenue | US$104.27k |
| Cost of Revenue | US$757.46k |
| Gross Profit | -US$653.19k |
| Other Expenses | US$7.89m |
| Earnings | -US$8.54m |
Last Reported Earnings
Nov 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.061 |
| Gross Margin | -626.46% |
| Net Profit Margin | -8,189.91% |
| Debt/Equity Ratio | 66.4% |
How did LXG.H perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/21 19:36 |
| End of Day Share Price | 2023/02/21 00:00 |
| Earnings | 2022/11/30 |
| Annual Earnings | 2022/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LexaGene Holdings Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sally Yanchus | Brookline Capital Markets |
| Neil Linsdell | iA Capital Markets |
| Chelsea Stellick | iA Capital Markets |